Team MyaLink has developed a solution to provide better care for patients with neurological orphan diseases. MyaLink believes that every patient—no matter the rarity of disease—should have access to a specialist when they need one. Physicians should be able to monitor patients over time and react to acute events when necessary.

The team has developed a platform solution for neurological orphan diseases that remotely monitors patients’ vital parameters and tracks their condition daily. Over time, physicians can get a better overview of disease progression, rather than a quick snapshot during an in-person visit. MyaLink can help prevent expensive crises and ICU stays through the early detection of severe situations. The real-world data can also be very valuable for novel orphan drug development and post-market surveillance. 

MyaLink’s first use case is myasthenia gravis (MG), a chronic orphan disease that causes muscle weakness and affects people of all ages. MG frequently fluctuates and affects the respiratory muscles, sometimes leading to life-threatening crises or death. Monitoring with MyaLink provides patients with support from a specialist when they feel unsafe and have urgent questions. If a patient’s vital parameters indicate an impending crisis, the physician can remotely adjust the dosage of immunosuppressive medication.

This can prevent a severe crisis, reduce the cost and burden of disease, and empower patients to cope with and manage their chronic condition.

MyaLink is powered by a team of neurologists and researchers and is part of the largest nationally certified integrated myasthenic center in Germany. MyaLink works with their tech partner, Qurasoft, and the German Myasthenia Association.